within Pharmacolibrary.Drugs.ATC.J;

model J05AE01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.04,
    Cl             = 0.00053,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.161,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005833333333333333,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.438,
    k12             = 110,
    k21             = 110
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AE01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Saquinavir is a protease inhibitor used as an antiretroviral agent in the treatment of HIV-1 infection. It was one of the first protease inhibitors approved for use but is now less commonly used due to newer agents with improved safety and efficacy. It is used in combination antiretroviral therapy for managing HIV/AIDS.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for HIV-infected adult patients, both male and female, under steady-state conditions receiving oral saquinavir-hardshell capsules 600 mg three times daily.</p><h4>References</h4><ol><li><p>Niemi, M, et al., &amp; Kivistö, KT (2003). Pharmacokinetic interactions with rifampicin : clinical relevance. <i>Clinical pharmacokinetics</i> 42(9) 819–850. DOI:<a href=\"https://doi.org/10.2165/00003088-200342090-00003\">10.2165/00003088-200342090-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12882588/\">https://pubmed.ncbi.nlm.nih.gov/12882588</a></p></li><li><p>Buchanan, CM, et al., &amp; Wempe, MF (2008). Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-beta-cyclodextrin formulations. <i>Biomacromolecules</i> 9(1) 305–313. DOI:<a href=\"https://doi.org/10.1021/bm700827h\">10.1021/bm700827h</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18072746/\">https://pubmed.ncbi.nlm.nih.gov/18072746</a></p></li><li><p>Hu, Z, et al., &amp; Zhou, S (2005). Herb-drug interactions: a literature review. <i>Drugs</i> 65(9) 1239–1282. DOI:<a href=\"https://doi.org/10.2165/00003495-200565090-00005\">10.2165/00003495-200565090-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15916450/\">https://pubmed.ncbi.nlm.nih.gov/15916450</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AE01;
